Germany DACH should become a powerhouse for the Group Germany is emerging as a key growth and launch market for Ipsen, with the DACH region now ranking as the Group’s leading European affiliate and gaining momentum across Oncology, Rare Disease and Neuroscience. As Ipsen enters its next phase of growth, new…
Europe Europe accounts for a substantial share of Takeda’s business, hosts a significant slice of the company’s manufacturing footprint, and is involved in around half of its late-stage trials and priority development programmes. As the group prepares potential launches in narcolepsy, psoriasis and polycythaemia vera, a rare blood cancer, Gamze Yuceland explains how patient insight,…
CEE Patients with cancer in Central and Eastern Europe wait an average of 705 days longer for access to new medicines than those in Western Europe. Closing that gap is the mandate Carole Coudray was given when she took the helm of BeOne Medicines’ Incubator Cluster earlier this year. As GM…
Europe Genmab is moving into one of the most consequential chapters in its history, as decades of antibody innovation converge with an ambition to take greater ownership of the journey from science to patient. With a European commercial organisation taking shape, opening the way for independently led launches, and a late-stage…
China Excalipoint is betting that the next chapter of T-cell engagers will be written in solid tumours, where the modality is beginning to challenge the boundaries of cancer immunotherapy. Co-Founder, Chairman and CEO/CSO Dr Lei Fang explains how two decades of T-cell research underpin a differentiated pipeline, a China-first global development…
Korea Korea’s real strength right now is active, innovative discovery research, and that expertise, along with international networking, keeps improving Jungwon Woo, MedPacto CEO, discusses translating innovative cancer research into clinical development, with a focus on TGF-beta and tumour microenvironment targeting. She highlights MP010’s potential, early clinical progress and partnership opportunities,…
Korea Even a truly great medicine delivers limited value if patients cannot actually benefit from it Jeong Tae Kim, General Manager of Daiichi Sankyo Korea, has spent 18 years with the company, including regional roles based in Tokyo before returning to head the Korean affiliate. He spoke to us about managing…
Korea With the bioPROTAC platform, we can, in principle, degrade essentially any problematic protein Jaehyun Choi, Co-CEO of Genexine, outlines the company’s transition from its established hyFc platform towards bioPROTAC, a novel protein degradation technology. He discusses GX-BP1, partnerships, regulatory challenges in Asia, and Genexine’s strategy of validating the platform through…
Europe Childhood cancer survival rates in high-income countries now exceed 80 percent, but that masks a more uneven picture: paediatric drug development lags far behind adult oncology, follow-up and psychosocial care remain patchy across Europe, and survivors can face life-altering side effects that surface decades after treatment ends. Carina Schneider and…
Korea Vaxcellbio aims to become a genuine game changer in the global immune cell therapy market Dr Je-Jung Lee, CEO of Vaxcellbio, discusses how his experience as a physician and immunotherapy researcher shaped the company’s patient-centred mission. He outlines Vaxcellbio’s differentiated NK cell, CAR-T and CAR-MIL platforms, manufacturing strategy, Korea’s evolving…
Saudi Arabia Mostafa Abdelrahman, General Manager of Lilly Saudi Arabia, discusses the company’s evolution from medicine supplier to healthcare partner, supporting Vision 2030 through innovation, public-private collaboration and localisation. He highlights advances in obesity, Alzheimer’s disease and oncology, alongside technology transfer, clinical research and talent development, while outlining priorities to expand patient…
Korea Our mission has remained constant: to develop and provide cancer patients with precise treatment and early detection, and to improve patient outcomes Dr. Tae-You Kim, CEO and Co-Founder of IMBdx, discusses the company’s liquid biopsy technology, AI-driven genomic analysis and ambition to build a global precision oncology platform. He outlines…
See our Cookie Privacy Policy Here